VACHHIGH SIGNALOPPORTUNITY10-K

VACH has entered into a definitive Business Combination Agreement with Veraxa Biotech AG, transitioning from a blank check SPAC actively seeking targets to having a confirmed merger partner.

This represents a major milestone for the SPAC as it moves from the target-searching phase to executing a definitive business combination with a Swiss biotech company. The complex structure involving formation of Swiss and Cayman entities suggests a sophisticated international transaction that will likely transform VACH's business profile entirely from a cash shell to an operating biotech entity.

Comparing 2026-03-10 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows signs of a SPAC in active deal execution, with current liabilities surging over 3,200% to $1.3M likely reflecting transaction-related costs and obligations, while current assets declined 73% to $194K as cash is deployed for deal activities. Despite significantly higher operating losses expanding from -$703K to -$1.8M, net income more than doubled to $9.0M, suggesting substantial non-operating gains potentially from warrant revaluations or other financial instruments typical in SPAC transactions. The deteriorating balance sheet metrics appear consistent with a SPAC nearing business combination completion rather than fundamental business distress.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+3221.1%
$39K→$1.3M

Current liabilities surged 3221.1% — significant near-term obligations; verify ability to meet short-term debt.

Operating Income
P&L
-154%
-$703K→-$1.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
+117.1%
$4.1M→$9.0M

Net income grew 117.1% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
-72.8%
$712K→$194K

Current assets declined 72.8% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
+30.9%
-$703K→-$486K

Operating cash flow surged 30.9% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-15.6%
-$11.4M→-$13.1M

Equity decreased 15.6% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+10.4%
$12.1M→$13.3M

Liabilities increased 10.4% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-31
ADDED
There were 25,300,000 Class A ordinary shares, par value $0.0001 per share, issued and outstanding and 6,325,000 Class B ordinary shares, par value $0.0001 per share, issued and outstanding as of March 10, 2026.
Certain Relationships and Related Transactions, and Director Independence.
Proposed Business Combination On April 22, 2025, we entered int a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the BCA ), with Veraxa Biotech AG, a company duly organized, validly existing, and in good standing under the laws of Switzerland ( Veraxa ) and Oliver Baumann, an individual, solely in his capacity as representative for the Company Shareholders.
Pursuant to the terms of the BCA, Voyager Acquisition Sponsor Holdco LLC, a Delaware limited liability company ( Sponsor ), will form a public limited company organized under the Laws of Switzerland ( PubCo whose legal name is referred to in the Joinder Agreement described below), and PubCo will form an exempted company limited by shares incorporated under the laws of the Cayman Islands, to be a direct wholly owned subsidiary of PubCo ( Merger Sub whose legal name is referred to in the Joinder Agreement described below, and, together with PubCo each, individually, an Acquisition Entity ).
Each such Acquisition Entity shall enter into a joinder to the BCA, in form and substance satisfactory to Veraxa.
+7 more — sign up free →
REMOVED
There were 25,300,000 Class A ordinary shares, par value $0.0001 per share, outstanding as of March 31, 2025.
We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us.
We will be required to evaluate our internal control procedures for the fiscal year ending December 31, 2024 as required by the Sarbanes-Oxley Act.
Holders As of December 31, 2024, there were eleven holders of record of our securities, one holder of record of our Class A ordinary shares, eight holders of record of our Class B ordinary shares, one holder of record of our Public Warrants and three holders of record of our Private Placement Warrants.
However, if our initial shareholders or management team acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the prescribed time period On January 24, 2024, the SEC adopted the 2024 SPAC Rules, which became effective on July 1, 2024.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →